Experiences with pain management for survivors of complex cancers: Focus on opioids and cannabis.

Authors

null

Talya Salz

Memorial Sloan Kettering Cancer Center, New York, NY

Talya Salz , Susan Chimonas , Sankeerth Jinna , Jessica Brens , Anuja Kriplani , Andrew L. Salner , Guilherme Rabinowits , Maria Currier , Robert Michael Daly , Deborah Korenstein

Organizations

Memorial Sloan Kettering Cancer Center, New York, NY, mskcc, New York, NY, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, Hartford Hospital, Hartford, CT, Miami Cancer Institute, Miami, FL

Research Funding

U.S. National Institutes of Health
U.S. National Institutes of Health

Background: Survivors of complex cancers often experience pain. Clinical practice guidelines for pain management in cancer survivors cautiously recommend opioids and cannabis for subgroups with certain pain phenotypes, despite limited evidence regarding benefits and harms in survivor populations. We aimed to better understand pain management for these survivors, focusing on attitudes toward, and experiences with, opioids and cannabis. Methods: We conducted 7 90-minute focus groups with 26 disease-free survivors of head and neck and lung cancer who still experience cancer-related pain. Multiple coders conducted thematic analyses to identify themes regarding 1) experiences with post-treatment pain and pain management and 2) utilization, benefits, and harms of post-treatment cannabis and opioids. Results: Survivors (7-35 months from treatment completion) experienced post-treatment physical and psychological pain that affected multiple aspects of their daily life. Since treatment completion, 69% used opioids previously and 8% currently using. Fifty-four percent had used any cannabis product since treatment completion, and 35% currently use cannabis. While some survivors experienced no pain management challenges, others enumerated various difficulties, including fears of addiction to opioids or cannabis, perceived stigma around both products, and access challenges around provider attitudes, cost and insurance coverage, and legality. Survivors reported that providers did not know how to advise about cannabis; for example: “When I talked [to providers] about marijuana they didn’t want to talk about it. They couldn’t recommend it because there’s no clinical data.” Opioids were often perceived as critical to pain management but came with unpleasant side effects. Cannabis was effective at reducing both pain and anxiety for many, but not all, survivors. For some, cannabis reduced anxiety, which in turn reduced pain: “It just keeps my mind occupied enough where I’m not thinking of pain.” Reducing anxiety also helped some survivors eat: “I have a lot of anxiety around eating because I have a fear of choking, so sometimes it helps that.” Survivors described a balance of benefits and harms of opioids and cannabis; for example: “Where [the doctor has] me now...if I go down any lower, it's not going to work. If I go up any higher, I'm going to be not able to function.”Conclusions: Post-treatment survivors of complex cancers continue to experience cancer-related pain, both psychological and physical, for which both opioids and cannabis present a complex set of harms and benefits that vary across survivors. Providers who care for cancer survivors should be aware of the interplay between psychological and physical pain, patient concerns and stigma around opioids and cannabis, and nuances of the harms, benefits, and access issues regarding these treatments.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Symptoms and Survivorship

Track

Symptom Science and Palliative Care

Sub Track

Palliative Care and Symptom Management

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 12118)

DOI

10.1200/JCO.2023.41.16_suppl.12118

Abstract #

12118

Poster Bd #

486

Abstract Disclosures

Similar Abstracts

Abstract

2023 ASCO Annual Meeting

The impact of music therapy on opioid use in cancer survivors with chronic pain.

First Author: Joke Bradt

First Author: Brooke Worster

Abstract

2023 ASCO Quality Care Symposium

The role of primary care in opioid prescribing for head and neck cancer (HNC) survivors.

First Author: Talya Salz